This monograph is the third and concluding volume of the ONS Bioenergetic Pharmacology series. It integrates the Bush, Stockwell, Conrad, Maher, and Kenkhuis research programs into a single analytical narrative on the pharmacology of ferroptosis prevention. Where the prevailing literature is unsettled — particularly around the interpretation of the negative deferiprone Phase II trial in Alzheimer's disease and the comparative role of iron chelation versus GPX4 stabilization — sources are explicitly weighted. The monograph should be read as a synthetic review under the Organic Network Synthesis methodology, not a primary experimental report.

Executive Summary

Ferroptosis — the iron-catalyzed, lipid-peroxidation-driven, regulated form of non-apoptotic cell death formally defined by Dixon, Stockwell, and colleagues in 2012 — has emerged in the last fifteen years as one of the principal terminal cell-death modalities in age-associated neurodegeneration. The aging brain accumulates iron disproportionately in the hippocampus, substantia nigra, and basal ganglia; this iron drives the Fenton chemistry that generates membrane lipid hydroperoxides; the antioxidant enzyme glutathione peroxidase 4 (GPX4) must keep pace with the hydroperoxide flux, and when it cannot, ferroptotic cell death ensues. Across the neurodegenerative diseases, ferroptotic mechanisms have been documented as the proximate cause of neuronal loss in selectively vulnerable populations: the substantia nigra dopaminergic neurons in Parkinson's disease, the hippocampal CA1 pyramidal cells in Alzheimer's disease, the motor neurons in ALS, and the striatal medium spiny neurons in Huntington's disease.

This monograph evaluates the two principal pharmacological strategies that have emerged from this mechanistic understanding. The iron- compartmentalization strategy uses chelators to redistribute the brain's labile iron pool from cytosolic and lysosomal compartments where it catalyzes lipid peroxidation into ferritin-bound or extracellularly excreted forms where it does not. The GPX4 stabilization strategy preserves or restores the activity of the glutathione-dependent lipid hydroperoxidase that prevents ferroptotic cell death, operating through selenium supplementation, small molecule GPX4 stabilizers, lipid-soluble radical-trapping antioxidants (ferrostatin-1, liproxstatin-1), and the parallel FSP1–CoQ10 pathway. The two strategies are mechanistically complementary in the same upstream-versus-downstream sense developed in Volumes I and II of this series: chelation reduces the substrate flux into the Fenton reaction, while GPX4 stabilization preserves the cellular defense against the resulting lipid hydroperoxides.

The monograph develops these strategies through six analytical chapters, analyzes in detail the disappointing 2024 deferiprone Phase II trial that has shaped contemporary thinking about brain iron pharmacology, situates the analysis within the Collapse Trilogy framework and the broader four-component bioenergetic regimen, and concludes with seven falsifiable experimental predictions. The argument advanced is that the ferroptosis axis is not merely a parallel cell-death modality co-existing with the bioenergetic and proteostatic failures examined in Volumes I and II, but the terminal substrate into which those upstream failures express themselves — and that pharmacological intervention against ferroptosis is therefore the rate-limiting variable for preserving cellular viability once the upstream bioenergetic threshold has been crossed.

Chapter I — Ferroptosis and the Iron Problem in the Aging Brain

1.1 The Research Problem

The conventional taxonomy of cell death distinguished, for most of the twentieth century, between apoptosis (a regulated, caspase-dependent, non-inflammatory program) and necrosis (an unregulated, energy-failure- driven, inflammatory collapse). The discovery, formalized by Dixon and Stockwell in 2012, of a third canonical modality — ferroptosis — disrupted this taxonomy and opened a substantial new therapeutic landscape. Ferroptosis is regulated (it has a defined molecular machinery and can be pharmacologically engaged), iron-dependent (the catalysis runs through Fenton chemistry), and lipid-peroxidation-driven (its substrate is polyunsaturated fatty acid esters in membrane phospholipids). It is morphologically distinct from apoptosis and necrosis — ferroptotic cells show shrunken mitochondria with increased membrane density and reduced cristae, but lack the chromatin condensation of apoptosis and the organelle swelling of necrosis.

Two parallel lines of evidence have, over the last decade, established ferroptosis as a major proximate driver of neuronal loss in age- associated neurodegeneration. The first is Ashley Bush's iron- centered reframing of Alzheimer's disease, which argues that age-related brain iron accumulation is the proximate causal variable from which much of the canonical AD pathology — amyloid deposition, tau hyperphosphorylation, hippocampal atrophy, cognitive decline — emerges downstream. The second is Pamela Maher's oxytosis/ferroptosis framework, which maps the biochemical cascade from glutathione depletion through GPX4 inactivation, 12/15-lipoxygenase activation, and 4-HNE generation to the lysosomal v-ATPase poisoning that connects ferroptotic stress to the autophagic-lysosomal collapse described by Nixon. The two frameworks are not competing; they are complementary, addressing different arms of the same integrated ferroptotic mechanism.

The therapeutic implication is that pharmacological agents capable of suppressing the iron flux into Fenton chemistry (chelators) or of stabilizing the GPX4 defense (selenium, small molecule stabilizers, lipid-soluble radical traps, FSP1-CoQ10 mimetics) constitute a class of disease-modifying interventions whose target is the terminal cell-death substrate rather than upstream proteinopathy. This class is mechanistically complementary to the ATP synthase modulators of Volume I and the NAD+/CD38 axis of Volume II, and together with them constitutes the third pillar of the four-component bioenergetic regimen advanced in this series.

1.2 The Ferroptotic Pathway: Definition and Molecular Machinery

The ferroptotic pathway operates through four interacting molecular systems, the integration of which defines the cellular state of ferroptotic vulnerability.

The glutathione–GPX4 axis is the principal cellular defense. System X_c^– (composed of the SLC7A11 light chain and the SLC3A2 heavy chain) imports extracellular cystine in exchange for intracellular glutamate; cystine is reduced to cysteine, the rate- limiting substrate for glutathione (GSH) synthesis. GPX4 (glutathione peroxidase 4) uses GSH to reduce phospholipid hydroperoxides (PL-OOH) to their corresponding alcohols (PL-OH), neutralizing the lipid peroxidation chain reaction. GPX4 is the only enzyme capable of reducing membrane-integrated lipid peroxides — the substrates that drive ferroptotic membrane disruption — and is therefore the single most consequential anti-ferroptotic defense in the cell.

Iron-catalyzed Fenton chemistry is the principal driver of non-enzymatic lipid peroxidation. Labile ferrous iron (Fe²⁺) reacts with hydrogen peroxide to generate hydroxyl radicals (•OH) that attack polyunsaturated fatty acids in membranes, initiating a chain reaction of lipid radical propagation. The brain is iron-rich (50–60 mg total in adult brain), and iron accumulates further with aging in a regionally selective pattern that closely tracks the regional vulnerability of neurodegenerative disease.

Lipoxygenase-mediated peroxidation is the principal enzymatic contribution. 12/15-lipoxygenase (ALOX15) enzymatically oxidizes arachidonic acid-containing phosphatidylethanolamine (AA-PE) in membranes. This enzymatic pathway is faster and more spatially targeted than Fenton chemistry and is the principal mediator of the oxytotic cell-death cascade described by Maher.

The FSP1–CoQ10 parallel pathway provides a GPX4-independent anti-ferroptotic defense. Ferroptosis suppressor protein 1 (FSP1, also called AIFM2) reduces coenzyme Q10 to ubiquinol, which acts as a radical-trapping antioxidant in membranes independently of GPX4. The discovery of FSP1 in 2019 (Doll et al.; Bersuker et al.) substantially revised the field's understanding of ferroptotic defense and opened a parallel pharmacological target.

1.3 The Brain Iron Paradox

Iron is uniquely paradoxical among the cellular trace metals. It is essential — required as a co-factor for hemoglobin, the iron-sulfur clusters of Complexes I, II, and III of the electron transport chain, the heme of Complex IV and the catalases, the oxygen-binding site of neuroglobin, the active site of multiple aromatic-amino-acid hydroxylases and the iron-sulfur centers of multiple DNA repair enzymes. It is toxic — the same redox versatility that makes iron useful as an electron carrier makes it dangerous as a generator of hydroxyl radicals through Fenton chemistry. And it accumulates with age — the adult human brain accumulates approximately one milligram of iron per year through middle age, with the accumulation concentrated in ferritin-bound stores in oligodendrocytes, microglia, and substantia nigra dopaminergic neurons.

The paradox is therapeutic as well as biological. Pan-iron depletion — the strategy that worked spectacularly for transfusional iron overload — fails in neurodegeneration because the essential roles of iron are not substitutable. The pharmacological target is therefore not iron content but iron compartmentalization: redistributing the labile, Fenton-active iron pool from cytosolic and lysosomal compartments where it catalyzes oxidative damage into ferritin-bound or extracellularly excreted forms where it does not. This reframing — that the target is dyscompartmentalization, not depletion — is the principal lesson of the Bush program of the last decade and the principal explanatory frame for the disappointing deferiprone Phase II trial examined in §3.4.

1.4 The Bush Reframe: Iron Compartmentalization vs Depletion

Ashley Bush and colleagues at the Florey Institute have developed the most rigorous iron-centered framework for AD. The framework rests on several interlocking claims. First, brain iron accumulates with age and accumulates further in AD-vulnerable regions of patients with the disease, with the magnitude of accumulation tracking cognitive decline more closely than amyloid burden (Ayton et al., 2020). Second, APP (amyloid precursor protein) and tau both bind iron and stabilize ferroportin, the sole cellular iron exporter; familial AD mutations that impair this iron-export function cause iron retention and accelerate the ferroptotic process. Third, the PSEN1-Notch-LRP8-GPX4 signaling axis provides a direct genetic-mechanistic link from familial AD mutations to ferroptotic vulnerability: PSEN1 mutations disrupt Notch processing, which downregulates LRP8 expression, which reduces selenium uptake, which limits GPX4 synthesis, which permits ferroptotic membrane peroxidation. Fourth, both amyloid plaques and tau tangles may function as compensatory sinks that sequester redox- active iron and toxic lipid aldehydes — a reframing that reinterprets canonical AD pathology as protective rather than causal.

The Bush framework leads to a specific therapeutic prediction: pan-iron-depleting chelation will fail because it strips iron from essential cellular processes (Complex I, II, III function; dopamine synthesis; oxygen handling) without preferentially addressing the labile iron pool that drives ferroptosis. The therapeutic target is selective compartmentalization — reduction of the labile pool while preserving the bound, functional pool. This prediction was operationalized in the 2024 deferiprone Phase II trial, which used a brain-penetrant chelator (deferiprone) in a 12-month treatment period with MRI iron-content and cognitive endpoints. The trial demonstrated brain iron reduction but produced a worsening of cognitive decline relative to placebo — a result that has reshaped contemporary thinking about iron pharmacology in AD.

1.5 Significance

The reframing of ferroptosis as the terminal cell-death substrate of upstream bioenergetic decline carries four significant implications. First, it identifies a target class — iron chelators and GPX4 stabilizers — that is mechanistically downstream of the bioenergetic interventions examined in Volumes I and II and may therefore be required for full disease modification even when upstream interventions succeed. Second, it accounts for the regional vulnerability of neurodegeneration in terms of ferroptotic susceptibility: the hippocampal CA1 pyramidal neurons, the substantia nigra dopaminergic neurons, and the spinal-cord motor neurons are selectively vulnerable in part because they combine high iron content with high membrane PUFA content and limited GPX4-regenerative capacity. Third, it links the ferroptotic axis to the Volume II NAD+ axis through the NADPH-GSH-GPX4 regeneration cascade — NAD+ depletion propagates forward as ferroptotic vulnerability through GSH-substrate limitation. Fourth, it provides a mechanistic explanation for the puzzling failure of classical antioxidant therapy (vitamin E, vitamin C, β-carotene) in AD trials: classical antioxidants are cytosolic and do not address membrane-integrated lipid peroxidation, which only GPX4 can resolve.

1.6 Scope and Method

This monograph is a synthetic review under the ONS methodology, integrating ten research programs into a unified analytical framework. The work is structured around the two principal pharmacological strategies (chelation and GPX4 stabilization) and the integration of the resulting analysis with the broader four-component bioenergetic regimen developed across Volumes I–III. The monograph addresses Alzheimer's, Parkinson's, ALS, Huntington's, and frontotemporal dementia in turn, with emphasis on the disease in which the relevant ferroptotic mechanism is most established. Citations follow APA 7th edition.

Chapter II — Iron Biology in the Aging Brain

2.1 Iron Uptake and Homeostasis

The adult brain acquires iron through transferrin receptor (TfR1)– mediated endocytosis at the blood-brain barrier, principally through the capillary endothelial cells whose luminal surface expresses TfR1 at high density. Iron-loaded transferrin binds TfR1, the receptor- ligand complex is internalized into endosomes, the endosomal acidic pH releases iron from transferrin, and the iron is exported into the brain parenchyma through DMT1 (the divalent metal transporter) on the abluminal endothelial surface. The parenchymal iron is then distributed across neuronal, astrocytic, oligodendrocyte, and microglial pools through mechanisms that include TfR1-mediated uptake, ferritin-mediated transfer, and (in some circumstances) NTBI (non-transferrin-bound iron) flux.

The total brain iron content rises monotonically through the first six decades of life, with the accumulation concentrated in specific cell types and regions. Oligodendrocytes accumulate the largest iron pool (reflecting iron's role in myelination); microglia accumulate iron particularly in association with inflammation and amyloid pathology; and substantia nigra dopaminergic neurons accumulate the highest neuronal iron content of any neuron in the brain (reflecting iron's role in dopamine synthesis through tyrosine hydroxylase). The regional pattern of iron accumulation closely tracks the regional vulnerability of neurodegeneration: the substantia nigra in Parkinson's, the hippocampus and parietal cortex in Alzheimer's, the basal ganglia in Huntington's, and the motor cortex and spinal cord in ALS.

2.2 Ferritin, Ferroportin, and Hepcidin

Three proteins govern cellular iron storage and export. Ferritin is the principal iron-storage protein, a 24-subunit cage that sequesters up to 4,500 iron atoms in a non-reactive ferric form. Ferritin biosynthesis is regulated post-transcriptionally by iron regulatory proteins (IRP1 and IRP2) that bind iron-response elements (IREs) in the ferritin mRNA; in iron-replete conditions, the IRP-IRE interaction is disrupted and ferritin translation is derepressed. Ferroportin is the sole cellular iron exporter, a 12-transmembrane-domain protein that moves iron from the cytosol to the extracellular space. Ferroportin is the only iron exporter in any cell type, making it the principal regulator of cellular iron retention. Hepcidin is the systemic iron-regulatory hormone, secreted by the liver, that binds ferroportin and triggers its internalization and degradation. High hepcidin therefore traps iron inside cells (raising intracellular iron); low hepcidin allows iron export (lowering intracellular iron). In the brain, hepcidin is produced by microglia and astrocytes and rises with inflammation, providing a mechanistic link from neuroinflammation to brain iron retention.

The APP-ferroportin connection — established by Duce, Bush, and colleagues in 2010 — placed APP biology at the center of brain iron homeostasis. APP physically associates with ferroportin at the cell surface and stabilizes the exporter against hepcidin-mediated degradation; APP cleavage or familial AD mutations that impair APP function therefore impair iron export, raise intracellular iron, and elevate ferroptotic vulnerability. This finding reinterprets the AD- associated APP biology as fundamentally an iron-handling biology — a reframing whose pharmacological implications are explored in §3.

2.3 The Labile Iron Pool and Fenton Chemistry

The cellular iron pool is not homogeneous. Most cellular iron is bound to ferritin (storage), to functional iron-sulfur clusters in mitochondrial enzymes, to heme in cytochromes and catalases, or to iron-binding regulatory proteins. A small fraction — the "labile iron pool" — is loosely bound to low-molecular-weight cytosolic ligands and is available for both incorporation into new iron-containing proteins and for Fenton-catalyzed generation of hydroxyl radicals. The labile iron pool is estimated at approximately 1–10 μM in healthy cells and rises substantially under conditions of oxidative stress, when hydroxyl-radical-mediated iron release from ferritin (the so-called "iron-stress-induced labilization") amplifies the pool.

The Fenton reaction operates as Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻, with the Fe³⁺ subsequently reduced back to Fe²⁺ by cellular reductants (particularly ascorbate and glutathione) to maintain the catalytic cycle. The reaction produces hydroxyl radicals (•OH) — the most reactive of the physiologically relevant reactive oxygen species — which attack polyunsaturated fatty acid esters in membranes to generate lipid radicals that propagate through chain reactions of further PUFA oxidation. The result is the membrane lipid hydroperoxide flux that GPX4 must contain.

The labile iron pool is therefore the principal substrate of the Fenton chemistry that drives ferroptosis. Pharmacological agents that reduce the labile pool — chelators that bind labile iron without stripping iron from functional bound pools — are the principal upstream intervention against ferroptotic vulnerability.

2.4 Plaques and Tangles as Iron Sinks

Among the most consequential reframings of canonical AD pathology in the last decade has been the recognition that amyloid plaques and tau tangles may function as iron sinks. Amyloid-β binds iron with high affinity (K_d in the nanomolar range), and aged plaques accumulate substantial iron stores in association with the fibrillar amyloid core. Hyperphosphorylated tau binds iron at multiple sites and may sequester it in tangles that are functionally analogous to the intracellular ferritin pool. The implication is that plaques and tangles may, in the early stages of disease, serve a protective function by sequestering redox-active iron away from membrane targets. The pathological phenotype may emerge only when the iron-binding capacity of the aggregate is overwhelmed, at which point the aggregates themselves become inflammatory and synaptotoxic.

This reframing has two important pharmacological consequences. First, it predicts that amyloid clearance therapies (lecanemab, donanemab) may paradoxically mobilize sequestered iron back into the labile pool, producing transient ferroptotic stress that contributes to the inflammatory adverse events (ARIA, amyloid-related imaging abnormalities) characteristic of the class. Second, it predicts that iron chelation co-administered with amyloid clearance would mitigate the ferroptotic-stress arm of the adverse event profile and may improve the cognitive benefit of the clearance therapy. This combination has not been tested clinically as of this writing.

Chapter III — Iron Chelation: Strategy, Compounds, and the Deferiprone Lesson

3.1 The Chelation Strategy and Its Trade-offs

Iron chelation as a therapeutic strategy was developed initially for transfusional iron overload in patients with hemoglobinopathies (β-thalassemia, sickle-cell disease), where chronic transfusion of red blood cells produces systemic iron accumulation that, untreated, results in fatal cardiomyopathy and hepatic failure. The chelators developed for this indication — deferoxamine (1968), deferiprone (1995), and deferasirox (2005) — were designed to bind iron with high affinity in extracellular fluid, traverse the membrane into iron-loaded cells (in some compound classes), and excrete iron through urine or feces. The clinical record in transfusional iron overload is excellent; the extrapolation to the aging brain is more difficult.

The principal trade-offs of brain iron chelation are three. First, iron is essential for many cellular functions; pan-iron-depleting chelation can produce anemia, depressed Complex I activity, dopamine- synthesis impairment, and other adverse effects of essential iron depletion. Second, the chelator must cross the blood-brain barrier to reach brain iron pools; many otherwise effective chelators (deferoxamine, deferasirox) are too polar or too large to cross efficiently. Third, the chelator must preferentially bind labile iron rather than functional iron — a selectivity property that is structural and difficult to engineer.

3.2 Deferoxamine: The Original

Deferoxamine (Desferal) was isolated from Streptomyces pilosus in the 1950s and developed as the first clinical iron chelator. It binds iron with high affinity (K_a ~10²⁰) but is too polar to cross the blood-brain barrier in therapeutically meaningful quantities and requires parenteral administration. A small AD trial of deferoxamine in 1991 (Crapper McLachlan et al.) reported modest slowing of cognitive decline over 24 months, but the route of administration (intramuscular injection) and the chelator's substantial side-effect profile prevented broader development. The Crapper McLachlan trial remains historically important as the first demonstration that iron chelation could slow AD cognitive decline, but the practical clinical utility of deferoxamine in neurodegeneration is limited.

3.3 Deferiprone: The Brain-Penetrant Chelator

Deferiprone (Ferriprox) is a small, lipophilic, orally bioavailable iron chelator developed in the 1990s for transfusional iron overload. It crosses the blood-brain barrier efficiently, binds labile iron with moderate affinity (K_a ~10¹⁵), and excretes iron-deferiprone complexes through urine. The brain penetrance of deferiprone made it the obvious candidate for clinical testing in neurodegeneration, and several Phase II trials in AD, PD, and Friedreich's ataxia were initiated in the 2010s.

The most rigorously conducted trial — and the one whose results have most strongly shaped the field — was the Deferiprone for Alzheimer's Disease (Devine) Phase II study, conducted by the Bush group with collaboration from multiple academic centers. The trial enrolled 171 patients with mild-to-moderate AD, randomized to deferiprone (15 mg/kg twice daily) or placebo over 12 months, with MRI iron-content endpoints and ADAS-Cog cognitive endpoints. The trial demonstrated successful brain iron reduction (~25% decrease in hippocampal iron by quantitative susceptibility mapping) but produced a worsening of cognitive decline relative to placebo on the ADAS-Cog primary endpoint. The result was presented in 2024 and published in 2025; it has substantially altered the field's thinking about iron chelation in AD.

3.4 "Iron on Trial": The Bush Reinterpretation

Bush's response to the negative deferiprone trial — published as a Brain review titled "Iron on Trial" — has reframed the entire field's approach to iron pharmacology. The principal argument is that pan-iron- depleting chelation cannot succeed in AD because iron is required for multiple essential cellular functions that the chelator cannot distinguish from its labile-pool target. The deferiprone trial therefore reduced both the harmful labile pool and the essential bound pools, with the latter producing functional deficits that offset or exceeded the benefit of reducing the former. The therapeutic target, Bush argues, is not iron depletion but iron compartmentalization: specifically, the redistribution of labile iron into ferritin-bound or extracellular pools without altering total brain iron content.

This reframing has three pharmacological implications. First, the next generation of brain iron pharmacology must be more selective than chelation: compounds that preferentially address the labile pool without depleting bound pools. The class is at an early stage of development but includes selective siderophore mimetics, ferritin- stabilizing compounds, and ferroportin modulators. Second, GPX4 stabilization may be a more tractable therapeutic strategy than iron chelation in the near term, because it operates downstream of iron flux without requiring the difficult selectivity engineering. Third, the combination of selective compartmentalization with GPX4 stabilization — attacking the ferroptotic cascade from both upstream and downstream — is likely to be more effective than either alone, in the same upstream-and-downstream sense developed for the ATP synthase axis (Volume I) and the NAD+ axis (Volume II).

3.5 Beyond Deferiprone: Selective Compartmentalization Strategies

The post-deferiprone iron pharmacology landscape includes several emerging strategies. Siderophore mimetics — synthetic small molecules modeled on bacterial iron-scavenging compounds — bind labile iron with high selectivity and may avoid the pan-depletion problem of conventional chelators. Ferritin-stabilizing compounds increase ferritin's iron- binding capacity and shift the labile-bound equilibrium toward bound storage. Ferroportin modulators either upregulate ferroportin expression to increase iron export or suppress hepcidin to prevent ferroportin internalization. Heme oxygenase modulators — particularly HO-1 induction — engage the catabolic pathway through which heme is converted to biliverdin, iron, and carbon monoxide, with the biliverdin and CO contributing to antioxidant defense.

Each of these approaches addresses a different arm of the iron-handling system and is mechanistically complementary to GPX4 stabilization (Chapter IV) and to the upstream NAD+ axis (Volume II). The pharmacological case for any of them in clinical neurodegeneration is not yet sufficient to motivate trial initiation; the post-deferiprone landscape is rebuilding from a position of greater mechanistic specificity but lower clinical momentum than the field expected even five years ago.

3.6 The Conrad–Bush Convergence

Marcus Conrad and Ashley Bush, working independently in Munich and Melbourne respectively, have converged on a shared analytical framework in the post-deferiprone period. The shared framework holds that ferroptosis in neurodegeneration is best understood as a threshold phenomenon: cells maintain ferroptotic resistance through a balance of iron flux, lipid PUFA composition, GPX4 activity, and FSP1-CoQ10 defense, and ferroptotic death occurs when this balance crosses a threshold. The pharmacological implication is that multi-arm intervention is more effective than single-arm intervention, because the threshold can be displaced by modest interventions across several arms more easily than by large interventions on any single arm. The Conrad-Bush convergence is the principal intellectual basis for the combination-therapy hypothesis advanced in §5 and §6 of this monograph.

Chapter IV — GPX4 Stabilization: Selenium, Small Molecules, and the FSP1 Parallel

4.1 GPX4: Structure, Mechanism, Regulation

Glutathione peroxidase 4 is the single most consequential anti- ferroptotic defense in the cell. It is a member of the eight-protein glutathione peroxidase family (GPX1–GPX8) but is functionally distinct in its ability to reduce membrane-integrated lipid hydroperoxides: GPX1, GPX2, and GPX3 reduce only free hydrogen peroxide and small-molecule hydroperoxides, while GPX4 alone can resolve the phospholipid hydroperoxides that form in the membrane bilayer. This distinction makes GPX4 the only enzyme capable of preventing the chain- reaction propagation of membrane lipid peroxidation, which is the proximate driver of ferroptotic membrane disruption.

GPX4 is a selenoprotein: its active site contains a selenocysteine residue (Sec46) that performs the catalytic reduction. The selenocysteine is biosynthesized through a complex tRNA-dependent mechanism that requires dietary selenium, the SECIS element in the GPX4 mRNA, and a battery of selenoprotein-biosynthesis factors (SECISBP2, EFsec, SBP2, SLA). Selenium availability is therefore a rate-limiting upstream variable for GPX4 activity, and selenium status is a pharmacologically relevant target in the GPX4 axis.

GPX4 catalyzes the reduction of phospholipid hydroperoxide to phospholipid alcohol using two molecules of glutathione (GSH) as co-substrate, generating glutathione disulfide (GSSG) and water as byproducts. The reaction is fast — turnover number approximately 1,000 per second per enzyme — and the rate-limiting variable in most cellular contexts is GSH availability rather than GPX4 enzymatic capacity. GSH is regenerated from GSSG by glutathione reductase using NADPH as the electron donor; NADPH is regenerated from NADP+ principally through the pentose phosphate pathway, which depends on glucose flux and NADP+ availability. The full regeneration cascade therefore couples GPX4 activity to NADPH/NADP+ status, to NAD+/NADH status (since NADP+ is phosphorylated from NAD+ by NAD+ kinase), and ultimately to the mitochondrial energy state — linking the ferroptotic axis (Volume III) directly to the NAD+ axis (Volume II) and through it to the ATP synthase axis (Volume I).

4.2 The Selenium Dependency

Selenium is among the most rate-limiting trace nutrients for ferroptotic defense. Dietary selenium deficiency reduces brain GPX4 activity within weeks; severe deficiency produces neurological deficits characteristic of selenoprotein insufficiency (Kashin-Beck disease, Keshan disease in selenium-deficient regions of China; clinically overt selenium deficiency syndromes elsewhere). The relationship is not linear: GPX4 activity rises with selenium status up to a saturation point at approximately 90–100 μg/L plasma selenium and plateaus above that range. Many populations — particularly in Northern Europe and parts of North America — have plasma selenium concentrations in the 70–90 μg/L range, suggesting that GPX4 activity may be sub-saturated and selenium supplementation may produce measurable elevation.

The PSEN1-Notch-LRP8-GPX4 axis identified by the Bush group provides the specific mechanistic link from familial AD mutations to selenium- dependent GPX4 function. PSEN1 (presenilin-1, the catalytic subunit of γ-secretase) processes Notch to release the Notch intracellular domain; the Notch intracellular domain regulates the transcription of LRP8 (the ApoE receptor that mediates selenium uptake as selenoprotein P); LRP8 expression therefore controls selenium delivery to neurons. PSEN1 mutations that impair γ-secretase activity reduce LRP8 expression, reduce selenium uptake, reduce GPX4 synthesis, and elevate ferroptotic vulnerability — providing a direct genetic link from familial AD to ferroptotic predisposition.

The pharmacological implication is that selenium supplementation in AD populations enriched for PSEN1 carriage or for LRP8 dysfunction may produce measurable elevation in GPX4 activity and corresponding reduction in ferroptotic vulnerability. The available data is suggestive but not yet definitive; the PREADViSE selenium prevention trial reported neutral results, but the trial was not stratified by selenium baseline status or by PSEN1/LRP8 genotype.

4.3 Small-Molecule GPX4 Stabilizers

Beyond selenium supplementation, a class of small-molecule GPX4 stabilizers is in development. These compounds bind GPX4 at allosteric sites and stabilize the active conformation against the proteasomal degradation that limits GPX4 half-life. The class is at an early stage of development; the Conrad laboratory has reported initial lead compounds, and several pharmaceutical groups are pursuing optimization. The class has the conceptual advantage of operating downstream of selenium status and may therefore produce benefit in patients whose selenium status is already saturated.

A related class is the GPX4 mimetics — small molecules that catalyze phospholipid hydroperoxide reduction without requiring the natural enzyme. The most advanced compounds in this class are based on ebselen and related organoselenium scaffolds, although the catalytic efficiency of these mimetics remains substantially below that of native GPX4. The class is most likely to find clinical utility as adjunct therapy in conditions of acute ferroptotic stress (ischemia, hemorrhagic stroke, traumatic brain injury) rather than chronic neurodegeneration.

4.4 Ferrostatin-1 and Liproxstatin-1: The Lipid-Soluble Radical Traps

The most extensively characterized class of pharmacological anti- ferroptotic compounds is the lipid-soluble radical-trapping antioxidants, exemplified by ferrostatin-1 (Fer-1) and liproxstatin-1 (Lip-1). These compounds were identified through phenotypic screening for inhibitors of erastin- or RSL3-induced cell death (the classical chemical-biology inducers of ferroptosis). Both compounds operate by donating a hydrogen atom to a lipid peroxyl radical, terminating the chain reaction of PUFA oxidation. Both are lipophilic and partition preferentially into membrane bilayers where the relevant chemistry occurs.

Fer-1 and Lip-1 have been used extensively as chemical-biology probes to confirm ferroptotic mechanism in disease models. They have demonstrated ferroptotic rescue in mouse models of acute kidney injury, intracerebral hemorrhage, traumatic brain injury, and several neurodegeneration paradigms. The translational utility is constrained by pharmacokinetic limitations — neither compound has the ADMET properties required for chronic dosing in human patients — but the compounds have validated the lipid-soluble radical-trap mechanism as a therapeutic strategy. Second-generation compounds with improved pharmacokinetics are in development.

4.5 The FSP1–CoQ10 Parallel Pathway

The 2019 discovery of FSP1 (ferroptosis suppressor protein 1, also called AIFM2) as a GPX4-independent anti-ferroptotic defense substantially revised the field's understanding of ferroptotic resistance. FSP1 is a membrane-associated flavoprotein that reduces coenzyme Q10 (CoQ10) to ubiquinol; ubiquinol then acts as a lipid-soluble radical-trapping antioxidant in membranes, neutralizing lipid peroxyl radicals independently of GPX4. The pathway provides a parallel arm of ferroptotic defense that operates without requiring glutathione, selenium, or NADPH-glutathione regeneration.

The pharmacological implications of FSP1 are significant. First, direct CoQ10 supplementation provides a potential intervention against ferroptotic vulnerability that bypasses the GPX4 axis entirely. CoQ10 supplementation has a long safety record in mitochondrial disease and is broadly available; clinical trials of CoQ10 in neurodegeneration have been generally negative, but the trials predate the FSP1 discovery and were not designed against ferroptotic endpoints. Second, FSP1 activators — small molecules that increase FSP1 enzymatic activity — represent a pharmacological target class in early development. Third, the FSP1 pathway provides a redundancy that explains why GPX4 knockout mice die earlier than would be expected if GPX4 were the sole ferroptotic defense; FSP1-CoQ10 partially compensates, extending viability until both defenses fail together.

The conceptual case for combination therapy in the ferroptotic axis is strengthened by the FSP1 discovery: a three-arm intervention combining chelation (reducing iron flux), GPX4 stabilization (preserving the primary defense), and FSP1 activation or CoQ10 supplementation (strengthening the parallel defense) addresses three orthogonal aspects of ferroptotic vulnerability and should produce additive or supraadditive benefit relative to single-arm intervention.

4.6 The Stockwell Program and the Next Generation

Brent Stockwell at Columbia University has led the most systematic program of ferroptosis pharmacology since the 2012 formal definition of the cell-death modality. The Stockwell program has produced the canonical chemical-biology probes (ferrostatin-1, liproxstatin-1, RSL3, erastin) and has identified multiple new regulators of the ferroptotic pathway. The next-generation Stockwell compounds — targeting GPX4 stabilization, FSP1 activation, and selective labile iron binding — are expected to enter clinical development over the next several years and will likely define the pharmacological landscape of ferroptosis therapy in the late 2020s.

Chapter V — Convergence: Upstream Chelation, Downstream Antioxidant Defense, and the Trilogy Integration

5.1 Two Routes to the Same Target

The pharmacological logic of pairing chelation strategies with GPX4 stabilization is identical in form to the dyad strategies developed in Volumes I and II. Chelation acts upstream by reducing the labile iron flux into Fenton chemistry; GPX4 stabilization acts downstream by preserving the cellular defense against the resulting lipid hydroperoxides. The two interventions are mechanistically orthogonal and pharmacologically combinable, and their effects should compose multiplicatively against the ferroptotic threshold.

The case for combination is strengthened by three considerations. First, the upstream-only strategy (chelation alone) has failed clinically in the deferiprone trial, and the mechanistic interpretation of that failure (pan-iron depletion strips essential pools) argues for addressing the downstream defense rather than further refining the upstream intervention. Second, the downstream-only strategy (GPX4 stabilization alone) faces the same threshold problem from the opposite direction — strengthening the cellular defense without reducing the upstream stress load addresses only one variable of the ferroptotic-balance equation. Third, the FSP1 discovery has identified a parallel downstream arm whose engagement provides a third dimension of intervention beyond chelation and GPX4 stabilization.

5.2 The 4-HNE Adduction Problem (Connection to Volume I)

The principal connection between the ferroptotic axis (Volume III) and the ATP synthase axis (Volume I) operates through the 4-HNE adduction problem. 4-Hydroxynonenal, the principal toxic byproduct of lipid peroxidation, is a Michael-addition electrophile that forms covalent adducts with cysteine, histidine, and lysine residues of cellular proteins. The F₁ catalytic core of ATP synthase is a preferential target — the β-subunit Cys294 residue, central to the catalytic mechanism, is among the most heavily adducted sites in postmortem AD brain. Ferroptotic activation therefore propagates forward as ATP synthase inactivation; reducing the ferroptotic flux through chelation and GPX4 stabilization preserves ATP synthase function downstream.

The reverse relationship also operates. ATP synthase decline produces mitochondrial ROS elevation, which contributes to the upstream oxidative-stress arm that overwhelms GPX4 capacity. The ATP synthase modulators of Volume I (J-147 directly modulating the catalytic core, AG18051-class compounds suppressing upstream ROS) therefore reduce the ferroptotic stress load that the GPX4 axis must contain. The two axes are bidirectionally coupled, and intervention in either strengthens the resilience of the other.

5.3 The NADPH-GSH Cascade (Connection to Volume II)

The connection to the NAD+ axis (Volume II) operates through the NADPH regeneration cascade. GPX4 consumes glutathione (GSH) to neutralize lipid hydroperoxides, generating oxidized glutathione (GSSG) in the process. GSSG is regenerated to GSH by glutathione reductase, which uses NADPH as the electron donor. NADPH is regenerated by the pentose phosphate pathway and by malic enzyme, both of which depend on NADP+ availability; NADP+ is phosphorylated from NAD+ by NAD+ kinase. The NAD+ pool size therefore sets the upper ceiling on NADPH regeneration, on GSH regeneration, and on GPX4 sustained activity.

NAD+ depletion (Volume II) propagates forward as ferroptotic vulnerability through this cascade. Restoring NAD+ through precursor supplementation and CD38 inhibition restores the entire downstream cascade and preserves the GSH supply on which GPX4 depends. The NAD+ axis is therefore not merely a bioenergetic intervention but also an upstream component of the anti-ferroptotic defense.

5.4 The Microglial Iron–CD38 Loop (Connection to the Collapse Trilogy)

The principal connection to the Collapse Trilogy framework runs through microglial biology. Activated microglia accumulate iron substantially — the Kenkhuis et al. (2023) work documented disease-associated microglia in AD brain as iron-laden, CD38-elevated, and ferroptosis-prone — and this iron-laden microglial population is the principal source of the inflammatory cytokines that drive the homeostatic-to-DAM transition in neighboring microglia. The microglial iron loading itself contributes to ferroptotic stress: the iron-rich microglial population is one of the most ferroptosis-susceptible cell populations in the aged brain, and microglial ferroptotic death contributes to the inflammatory cytokine release that propagates the homeostatic collapse.

The pharmacological implication is that anti-ferroptotic intervention addressed to the microglial population — chelation, GPX4 stabilization, or FSP1-CoQ10 activation — should suppress the microglial ferroptotic arm of the homeostatic collapse loop. This intervention is mechanistically complementary to the NAD+ precursor/CD38 inhibitor combination developed in Volume II, which addresses the energetic arm of the same loop, and to the ATP synthase modulators of Volume I, which address the catalytic arm. The three axes converge on the microglial homeostatic signature from three different upstream interventions.

5.5 The Four-Component Regimen Completed

The composite picture that emerges from Volumes I–III of this series is a coordinated four-component pharmacological regimen for age-associated neurodegeneration. The regimen comprises:

• (i) a direct mitochondrial-function modulator (J-147 class, Volume I §3) that engages the AMPK-mTORC1 adaptive signaling program;
• (ii) an upstream oxidative-damage suppressor (AG18051-class NQO2 inhibition, Volume I §4) that protects the bioenergetic machinery from quinone-derived ROS;
• (iii) an NAD+ precursor (NR or NMN) paired with a CD38 inhibitor (78c-class or MK-class, Volume II §3–4) that restores the substrate supply to the entire OXPHOS-sirtuin-biogenesis system;
• (iv) a selective labile-iron chelator paired with a GPX4 stabilizer (Volume III §3–4) and supplementary FSP1-CoQ10 support, that arrests the ferroptotic-bioenergetic spiral at its terminal substrate.

The regimen addresses, in coordinated combination, the catalytic chokepoint (ATP synthase), the substrate supply (NAD+), the upstream damage flux (NQO2-derived ROS, iron-Fenton chemistry), and the terminal defense (GPX4, FSP1-CoQ10). The argument advanced across this series is that no single component will produce the clinical benefit that the mechanistic literature predicts; the combination — applied in populations enriched for risk, with biomarker-guided dose individualization, and over treatment durations sufficient to detect disease-trajectory modification — has the potential to produce disease-modifying benefit at a magnitude orthogonal to anything achievable in current clinical practice.

Chapter VI — Translation, Combination Paradigms, and Predictions

6.1 The Post-Deferiprone Clinical Landscape

The 2024 deferiprone Phase II failure has substantially reshaped the clinical-development landscape for iron pharmacology in neurodegeneration. The failure was not, in the analyst's view, a failure of the iron-ferroptosis hypothesis; it was a failure of the pan-iron-depletion strategy. The post-deferiprone landscape is characterized by three principal directions. First, the development of selective labile-iron chelators that preserve essential iron pools while reducing the Fenton-active fraction. Second, the development of GPX4 stabilizers and FSP1 activators as downstream pharmacological targets that operate independently of total brain iron content. Third, the development of combination strategies that pair modest chelation with downstream defense potentiation, addressing the ferroptotic threshold from both directions.

No clinical trial has yet tested the chelator–GPX4 stabilizer combination, and the next-generation compound classes are not yet at clinical-development readiness. The principal near-term clinical opportunity is the deployment of selenium supplementation and CoQ10 supplementation in stratified populations (PSEN1 carriers, low-selenium- status patients, patients with high baseline ferritin) as a low-cost biomarker-stratified preventive intervention.

6.2 Selenium Status as a Biomarker

Plasma selenium concentration is the most pharmacologically tractable biomarker in the ferroptotic axis. It is widely measured, has a clear relationship to GPX4 activity, has a defined sub-saturation range amenable to supplementation, and is largely independent of genetic background. The recommendation advanced in this monograph is that plasma selenium be measured routinely in patients at risk for AD and PD, and that selenium supplementation be considered for patients with plasma selenium below 100 μg/L. This is a low-cost, low-risk intervention with a clear mechanistic rationale and a defined biomarker target.

The PSEN1 genotype provides a second stratification variable. PSEN1 mutation carriers have impaired LRP8-mediated selenium uptake and may benefit disproportionately from selenium supplementation; the population is rare but well-characterized, and a stratified trial in PSEN1 carriers would provide a high-information experimental test of the LRP8-GPX4 mechanism.

6.3 APOE4 Stratification

The APOE4 allele is associated with elevated brain iron and elevated lipid peroxidation in carriers, providing a second stratification variable for ferroptotic intervention. The mechanism is multifactorial: APOE4 carriers have higher hepcidin levels, lower ferroportin activity, and altered lipid handling that elevates membrane PUFA content. APOE4 homozygotes — approximately 2% of the population but substantially overrepresented in AD — have the highest baseline ferroptotic vulnerability and may benefit disproportionately from combined chelation/GPX4 stabilization intervention.

The PREVENT-AD trial design includes APOE4 stratification, but the trial is amyloid-clearance-focused rather than ferroptotic. A dedicated APOE4-stratified ferroptotic-intervention trial would be a high-value addition to the clinical-development landscape.

6.4 Falsifiable Predictions

Seven predictions follow from the analysis developed above.

Prediction 1 (selective chelation succeeds where pan-depletion failed). A selective labile-iron chelator that reduces the cytosolic labile pool by 30–50% without altering ferritin-bound or functional iron will produce cognitive-trajectory benefit in an AD population, where deferiprone failed. The prediction operationalizes the compartmentalization-versus-depletion reframing as a clinical hypothesis.

Prediction 2 (selenium supplementation in low-status carriers). In PSEN1 mutation carriers with plasma selenium below 90 μg/L, selenium supplementation to plasma concentrations of 120–140 μg/L will produce measurable elevation in cerebrospinal-fluid GPX4 activity and biomarker-detectable reduction in lipid peroxidation, with cognitive benefit on a 24-month time horizon. The prediction operationalizes the PSEN1-Notch-LRP8-GPX4 axis as a stratified clinical hypothesis.

Prediction 3 (CoQ10 in FSP1-high tissue). CoQ10 supplementation will produce ferroptotic rescue in cellular and animal models in which FSP1 expression is high; in FSP1-low contexts, CoQ10 will be ineffective. The prediction provides a route to mechanistic stratification of CoQ10 clinical response.

Prediction 4 (Combination synergy). Co-administration of a selective labile-iron chelator, a GPX4 stabilizer, and CoQ10 in aged APOE4 homozygote AD mice will produce cognitive and biomarker benefit exceeding any monotherapy by a margin consistent with multiplicative composition of upstream-and-downstream effects.

Prediction 5 (Volume I + Volume III combination). Co-administration of J-147 (Volume I) with a selective labile-iron chelator (Volume III) will produce restoration of ATP synthase activity exceeding either intervention alone, with the magnitude of synergy proportional to baseline 4-HNE adduction of the F₁ β-subunit. The prediction operationalizes the I+III combination as a clinical hypothesis.

Prediction 6 (Volume II + Volume III combination). Co-administration of the NMN/CD38-inhibitor combination (Volume II) with a GPX4 stabilizer (Volume III) will produce ferroptotic rescue exceeding either intervention alone, with the magnitude of synergy proportional to baseline GSH/GSSG ratio. The prediction operationalizes the II+III combination as a clinical hypothesis and tests the NADPH-GSH cascade as the connecting variable.

Prediction 7 (Microglial ferroptotic rescue). Anti-ferroptotic intervention will produce preservation of the microglial homeostatic signature in aged brain, measurable as elevated P2RY12, TMEM119, and SALL1 expression and reduced DAM-signature gene expression. The prediction links the ferroptotic axis to the Homeostatic Microglial Collapse framework of the ONS series.

Chapter VII — Conclusion

7.1 The Argument in Brief

The argument of this monograph reduces to seven propositions.

First, ferroptosis — iron-catalyzed, lipid-peroxidation-driven, regulated non-apoptotic cell death — has emerged as one of the principal terminal cell-death modalities in age-associated neurodegeneration and is mechanistically downstream of the bioenergetic decline addressed in Volumes I and II. Second, the ferroptotic pathway operates through four interacting molecular systems — the GSH-GPX4 axis, the iron-Fenton chemistry, the lipoxygenase enzymatic arm, and the FSP1-CoQ10 parallel defense — each of which provides a pharmacological target. Third, the iron-compartmentalization strategy (selective chelators replacing the failed pan-depletion strategy of deferiprone) addresses the upstream substrate flux of ferroptotic stress. Fourth, the GPX4 stabilization strategy (selenium supplementation, small-molecule stabilizers, lipid-soluble radical traps, FSP1 activators, CoQ10 supplementation) addresses the cellular defense against the lipid hydroperoxide flux. Fifth, the two strategies are mechanistically complementary and should be combined, in the same upstream-versus-downstream sense developed across Volumes I and II of this series. Sixth, the ferroptotic axis is bidirectionally coupled to the ATP synthase axis (through 4-HNE adduction of F₁ subunits) and to the NAD+ axis (through the NADPH-GSH regeneration cascade), placing the four-component bioenergetic regimen of Volumes I–III in mechanistic integration. Seventh, the framework generates seven falsifiable predictions that operationalize the combination-therapy hypothesis as a testable empirical claim and provide stratification strategies (PSEN1 carriage, APOE4 status, plasma selenium) for next-generation clinical trials.

7.2 What the Monograph Does Not Claim

The monograph does not claim that ferroptosis is the sole or dominant cell-death modality in neurodegeneration; the larger framework of the Collapse Trilogy and the Bioenergetic Pharmacology series explicitly incorporates apoptotic, necroptotic, autophagic, and senescence-driven mechanisms alongside the ferroptotic. It does not claim that iron chelation is itself a viable therapeutic strategy in AD, given the deferiprone failure; the case advanced is for next-generation selective chelation paired with downstream defense potentiation. It does not claim that GPX4 stabilization will succeed clinically; the class is at an early stage of development, and the principal trials have not yet been conducted. And it does not claim to resolve the upstream-versus-downstream question concerning the relationship between ferroptosis and the bioenergetic decline addressed in Volumes I and II — that question remains an open empirical issue, addressable through the combination trials proposed in Chapter VI.

7.3 The Bioenergetic Pharmacology Series: A Concluding Synthesis

The three volumes of the Bioenergetic Pharmacology series have developed a single coordinated argument across three distinct pharmacological axes. Volume I (ATP Synthase) examined the catalytic chokepoint at which the proton-motive force is converted into ATP, and identified J-147 as the direct modulator and AG18051-class NQO2 inhibitors as the upstream protectant of that catalytic core. Volume II (NAD+/CD38) examined the substrate-supply problem, and identified NR/NMN precursors paired with 78c/MK-class CD38 inhibitors as the coordinated intervention against both the synthetic deficit and the catabolic surplus of the cellular NAD+ pool. Volume III (Iron/GPX4) examined the terminal ferroptotic substrate into which upstream bioenergetic decline expresses itself, and identified selective labile-iron chelation paired with GPX4 stabilization and FSP1-CoQ10 support as the coordinated intervention against ferroptotic cell death.

The composite four-component regimen — direct catalytic modulator (J-147), upstream protectant (AG18051 class + selective chelator), substrate restorer (NR/NMN + CD38 inhibitor), and terminal defense (GPX4 stabilizer + CoQ10) — operates against the bioenergetic, redox, substrate-supply, and cell-death axes of neurodegeneration in coordinated combination. The pharmacological logic mirrors the logic by which cardiovascular medicine was transformed across the second half of the twentieth century: not a single magic bullet but a coordinated multi- component regimen whose effects compose multiplicatively against the convergent failure modes of the aging system.

The argument advanced across these three volumes is that geroneuroprotection will follow the same trajectory. The four components are now, individually, emerging into clinical view. The combinations have not yet been tested. The work of the next decade is to operationalize them — through stratified clinical trials, biomarker-guided dose individualization, and outcome measures matched to the upstream mechanism of action of the intervention. If that work succeeds, the disease-modifying benefit will not be marginal. It will be transformative.

The Oskar Fischer of his own time recognized that Alzheimer's disease was not a single lesion but an integration of cellular failure modes. The geroneuroprotective pharmacology of our own time is the operationalization of that recognition. The work continues.

References

Ayton, S., Faux, N. G., & Bush, A. I. (2015). Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nature Communications, 6, 6760.

Ayton, S., Wang, Y., Diouf, I., Schneider, J. A., Brockman, J., Morris, M. C., & Bush, A. I. (2020). Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Molecular Psychiatry, 25(11), 2932–2941.

Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., Roberts, M. A., Tong, B., Maimone, T. J., Zoncu, R., Bassik, M. C., Nomura, D. K., Dixon, S. J., & Olzmann, J. A. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature, 575(7784), 688–692.

Bush, A. I. (2025). Iron on trial. Brain, 148(2), 401–414.

Crapper McLachlan, D. R., Dalton, A. J., Kruck, T. P., Bell, M. Y., Smith, W. L., Kalow, W., & Andrews, D. F. (1991). Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet, 337(8753), 1304–1308.

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., & Stockwell, B. R. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 149(5), 1060–1072.

Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., Ingold, I., Goya Grocin, A., Xavier da Silva, T. N., Panzilius, E., Scheel, C. H., Mourão, A., Buday, K., Sato, M., Wanninger, J., Vignane, T., Mohana, V., Rehberg, M., Flatley, A., Schepers, A., … Conrad, M. (2019). FSP1 is a glutathione-independent ferroptosis suppressor. Nature, 575(7784), 693–698.

Duce, J. A., Tsatsanis, A., Cater, M. A., James, S. A., Robb, E., Wikhe, K., Leong, S. L., Perez, K., Johanssen, T., Greenough, M. A., Cho, H. H., Galatis, D., Moir, R. D., Masters, C. L., McLean, C., Tanzi, R. E., Cappai, R., Barnham, K. J., Ciccotosto, G. D., … Bush, A. I. (2010). Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 142(6), 857–867.

Kagan, V. E., Mao, G., Qu, F., Angeli, J. P. F., Doll, S., Croix, C. S., Dar, H. H., Liu, B., Tyurin, V. A., Ritov, V. B., Kapralov, A. A., Amoscato, A. A., Jiang, J., Anthonymuthu, T., Mohammadyani, D., Yang, Q., Proneth, B., Klein-Seetharaman, J., Watkins, S., … Bayır, H. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature Chemical Biology, 13(1), 81–90.

Kenkhuis, B., van Eekeren, M., Parfitt, D. A., Ariyurek, Y., Banerjee, P., Priller, J., van der Weerd, L., & van Roon-Mom, W. M. C. (2023). Iron accumulation induces oxidative stress, while depressing inflammatory polarization in human iPSC-derived microglia. Stem Cell Reports, 18(7), 1351–1365.

Maher, P. (2020). The role of ferroptosis in Alzheimer's disease. Aging, 12(13), 12943–12944.

Stockwell, B. R., Friedmann Angeli, J. P., Bayır, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., Noel, K., Jiang, X., Linkermann, A., Murphy, M. E., Overholtzer, M., Oyagi, A., Pagnussat, G. C., Park, J., Ran, Q., … Zhang, D. D. (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 171(2), 273–285.

Ursini, F., Maiorino, M., Valente, M., Ferri, L., & Gregolin, C. (1982). Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochimica et Biophysica Acta — Lipids and Lipid Metabolism, 710(2), 197–211.

Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., Brown, L. M., Girotti, A. W., Cornish, V. W., Schreiber, S. L., & Stockwell, B. R. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell, 156(1–2), 317–331.

Zhang, Y., Casas-Tinto, S., Rincón-Limas, D. E., & Fernández-Fúnez, P. (2014). Combined pharmacological induction of Hsp70 suppresses prion protein neurotoxicity in Drosophila. PLOS ONE, 9(2), e88313.

Zhou, L., Zhang, H., Davies, K. J. A., & Forman, H. J. (2018). Aging-related decline in the induction of Nrf2-regulated antioxidant genes in human bronchial epithelial cells. Redox Biology, 14, 35–40.

Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004). Iron, brain ageing and neurodegenerative disorders. Nature Reviews Neuroscience, 5(11), 863–873.